ClinicalTrials.gg
RecruitingNCT05681936Updated Nov 16, 2026

Functional and Structural Changes in the Central Nervous System Following Spinal Cord Injury

An observational study in Spinal Cord Injuries, Neurogenic Bladder Dysfunction and Degenerative Cervical Spinal Stenosis, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Zurich · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.
Updated Nov 16, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
225
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Spinal Cord Injuries by University of Zurich — 7 open to participants now, 7 under way, none of them phase 3. Spinal Cord Injuries · University of Zurich.

Planned enrollment
5th of 10
225 · median 204
Started
2023
the only one that year
Observational
10 of 24
4 open now
Registered
22nd of 24
by date

Among the 24 studies in Spinal Cord Injuries by University of Zurich, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2023, is one of 10 observational ones, and was the 22nd registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

7 of the 24 studies in Spinal Cord Injuries by University of Zurich are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Spinal Cord Injuries by University of Zurich, or all of them as a file.
02

Study summary

Building on recent improvements, state-of-the-art functional MRI will be applied as an advanced diagnostic tool for the lumbosacral cord in spinal cord injury (SCI) patients to characterize the remaining neuronal activity of the motor and sensory neurons. Alterations in the activity pattern will reveal the effect upon task-related spinal cord activity of the lower motor neurons and sensory neurons undergoing trauma-induced neurodegeneration, at a spatial specificity that has not been possible so far. Results of this study will be of crucial importance because SCI patients can only profit from regeneration-inducing therapies if spinal neuronal function is preserved below the level of lesion.

03

Conditions studied

  • Spinal Cord Injuries
  • Neurogenic Bladder Dysfunction
  • Degenerative Cervical Spinal Stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The participants will be recruited from the primary care clinic as well as via flyers distributed at hospital waiting rooms and patient support organisations.

Healthy controls will be recruited via public announcements and via flyers distributed at the primary care clinic and two universities.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • Willing to take part and follow requirements of the protocol

Patients additionally need to fulfil the following study-specific inclusion criteria:

Cross-sectional study:

  • Chronic traumatic SCI (> 12 months after injury) or
  • Diagnosed degenerative spondylotic myelopathy (DCM)

Longitudinal study:

  • Acute traumatic SCI (\< 2 months after injury) or
  • Patients with neurogenic lower urinary tract dysfunction (NLUTD) who undergo routine tibial nerve stimulation (TNS) treatment as part of their rehabilitation (but independently of this study) at Balgrist University Hospital

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • for MRI (presence of pacemaker or other type of stimulator in the body, presence of metallic foreign body in or on the body, etc.); we will comply with the imaging center's (SCMI) guidelines and in case of doubt we will exclude the participant from the study
  • No
  • History of psychiatric or neurological disease, apart from those induced by SCI (e.g.epilepsy)
  • History of skull opening or head trauma
  • Known or suspected non-adherence, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
  • Women who are pregnant (when uncertain, participants will undergo urine testing) or breastfeeding
  • Intention to become pregnant during the course of the study
  • (BMI) > 35
  • Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
225 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cross-sectional study: healthy controls
  • Cross-sectional study: chronic traumatic SCI patients
  • Cross-sectional study: non-traumatic SCI patients with degenerative spondylotic myelopathy
  • Longitudinal study: healthy controls
  • Longitudinal study: acute traumatic SCI patients (< 2 months after SCI)
  • Longitudinal study: patients with neurogenic lower urinary tract dysfunction
06

What researchers measure

Primary outcomes

  1. Cross-sectional study: lumbosacral functional fMRI

    Activations in the gray matter of the lumbosacral cord, as a response to sensory, motor, and somatosensory stimulations, or no stimulation (resting state). Spatiotemporal components of the BOLD signal as well as the couplings and anti-couplings between these components

    Time frame: Baseline only

  2. Longitudinal study: lumbosacral functional fMRI

    Activations in the gray matter of the lumbosacral cord, as a response to sensory, motor, and somatosensory stimulations, or no stimulation (resting state). Spatiotemporal components of the BOLD signal as well as the couplings and anti-couplings between these component

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  3. Cross-sectional study: brain functional MRI

    Activations in the cortical and subcortical areas of the brain as a response to sensory, motor, and somatosensory stimulations, or no stimulation (resting state)

    Time frame: Baseline only

  4. Longitudinal study: brain functional MRI

    Activations in the cortical and subcortical areas of the brain as a response to sensory, motor, and somatosensory stimulations, or no stimulation (resting state)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

Secondary outcomes

  1. Cross-sectional study: diffusion MRI in the spinal cord

    Directional diffusivities in the spinal cord (units of mm2/s)

    Time frame: Baseline only

  2. Cross-sectional study: diffusion MRI in the spinal cord

    Fractional anisotropy in the spinal cord (unitless)

    Time frame: Baseline only

  3. Longitudinal study: diffusion MRI in the spinal cord

    Directional diffusivities in the spinal cord, measured (units of mm2/s)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  4. Longitudinal study: diffusion MRI in the spinal cord

    Fractional anisotropy in the spinal cord (unitless)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  5. Cross-sectional study: structural MRI in spinal cord

    Cross-sectional areas of the spinal cord gray and white matter (units of mm2)

    Time frame: Baseline only

  6. Longitudinal study: structural MRI in spinal cord

    Cross-sectional areas of the spinal cord gray and white matter (units of mm2)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  7. Cross-sectional study: magnetic resonance neurography of the lumbosacral plexus

    Thickness of nerves and nerve roots (units of mm2)

    Time frame: Baseline only

  8. Cross-sectional study: magnetic resonance neurography of the lumbosacral plexus

    Nerve entry points into the spinal cord (for determining neurological levels)

    Time frame: Baseline only

  9. Longitudinal study: magnetic resonance neurography of the lumbosacral plexus

    Thickness of nerves and nerve roots (units of mm2)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  10. Longitudinal study: magnetic resonance neurography of the lumbosacral plexus

    Nerve entry points into the spinal cord (for determining neurological levels)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  11. Cross-sectional study: diffusion MRI in the brain

    Directional diffusivities in the brain (units of mm2/s)

    Time frame: Baseline only

  12. Cross-sectional study: diffusion MRI in the brain

    Fractional anisotropy in the brain (unitless)

    Time frame: Baseline only

  13. Longitudinal study: diffusion MRI in the brain

    Directional diffusivities in the brain (units of mm2/s)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  14. Longitudinal study: diffusion MRI in the brain

    Fractional anisotropy in the brain (unitless)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  15. Cross-sectional study: structural MRI in the brain

    Cortical thickness (units of mm)

    Time frame: Baseline only

  16. Cross-sectional study: structural MRI in the brain

    Volumes of the brain gray and white matter (units of mm3)

    Time frame: Baseline only

  17. Longitudinal study: structural MRI in the brain

    Cortical thickness (units of mm)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  18. Longitudinal study: structural MRI in the brain

    Volumes of the brain gray and white matter (units of mm3)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  19. Cross-sectional study: nerve conduction study

    Latencies of F waves (units of ms). Period between initial stimulation and F wave elicitation in the tibial and peroneal motor nerves.

    Time frame: Baseline only

  20. Cross-sectional study: nerve conduction study

    Amplitudes of F waves in the tibial and peroneal motor nerves (units of microV)

    Time frame: Baseline only

  21. Cross-sectional study: nerve conduction study

    Duration of F waves in the tibial and peroneal motor (units of ms)

    Time frame: Baseline only

  22. Longitudinal study: nerve conduction study

    Latencies of F waves (units of ms). Period between initial stimulation and F wave elicitation in the tibial and peroneal motor nerves.

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  23. Longitudinal study: nerve conduction study

    Amplitudes of F waves in the tibial and peroneal motor nerves (units of microV)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  24. Longitudinal study: nerve conduction study

    Duration of F waves in the tibial and peroneal motor (units of ms)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  25. Cross-sectional study: motor evoked potentials (MEP)

    Latencies (units of ms)

    Time frame: Baseline only

  26. Cross-sectional study: motor evoked potentials (MEP)

    Amplitudes (units of mV)

    Time frame: Baseline only

  27. Longitudinal study: motor evoked potentials (MEP)

    Latencies (units of ms)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  28. Longitudinal study: motor evoked potentials (MEP)

    Amplitudes (units of mV)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  29. Cross-sectional study: American Spinal Injury Association Impairment Scale (AIS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    AIS quantifies the severity of the spinal cord injury. AIS (ASIA Impairment Scale) grades from A-E, whereas grade A (complete spinal cord injury) is worse than grade E (no impairment)

    Time frame: Baseline only

  30. Cross-sectional study: Lower Extremities Motor Scale (LEMS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    LEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the lower limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic)

    Time frame: Baseline only

  31. Cross-sectional study: Upper Extremities Motor Scale (UEMS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    UEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the upper limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total UEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic)

    Time frame: Baseline only

  32. Cross-sectional study: Light touch (LT) score from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    The LT score is based on assessments of ISNCSCI and represents the sum of sensory function of 28 dermatome pairs in terms of light touch sensation. It consists of a 2-point scale (0=absent sensation; 1=altered (impaired or partial sensation, including hyperesthesia); 2 = normal or intact sensation) for each dermatome and body site. The lowest and highest possible LT score for one body site is 0 and 56, respectively

    Time frame: Baseline only

  33. Cross-sectional study: Pin prick (PP) score from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    The PP score is based on assessments of ISNCSCI and represents the sum of sensory function of 28 dermatome pairs in terms of pin prick discrimination. It consists of a 2-point scale (0=absent discrimination; 1=altered (impaired or partial discrimination); 2 = normal or intact discrimination) for each dermatome and body site. The lowest and highest possible PP score for one body site is 0 and 56, respectively

    Time frame: Baseline only

  34. Longitudinal study: American Spinal Injury Association Impairment Scale (AIS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    AIS quantifies the severity of the spinal cord injury. AIS (ASIA Impairment Scale) grades from A-E, whereas grade A (complete spinal cord injury) is worse than grade E (no impairment).

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  35. Longitudinal study: Lower Extremities Motor Scale (LEMS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    LEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the lower limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total LEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  36. Longitudinal study: Upper Extremities Motor Scale (UEMS) from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    UEMS is based on assessments of ISNCSCI and composed from the sum of muscle function grading of the five key muscles of the upper limbs. It consists of a 6-point scale (0=no; 5=normal activity) for each muscle and body site. The lowest possible score in the total UEMS score for one body site is 0 (symptomatic); the highest possible score is 50 (asymptomatic)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  37. Longitudinal study: Light touch (LT) score from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    The LT score is based on assessments of ISNCSCI and represents the sum of sensory function of 28 dermatome pairs in terms of light touch sensation. It consists of a 2-point scale (0=absent sensation; 1=altered (impaired or partial sensation, including hyperesthesia); 2 = normal or intact sensation) for each dermatome and body site. The lowest and highest possible LT score for one body site is 0 and 56, respectively

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  38. Longitudinal study: Pin prick (PP) score from the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol

    The PP score is based on assessments of ISNCSCI and represents the sum of sensory function of 28 dermatome pairs in terms of pin prick discrimination. It consists of a 2-point scale (0=absent discrimination; 1=altered (impaired or partial discrimination); 2 = normal or intact discrimination) for each dermatome and body site. The lowest and highest possible PP score for one body site is 0 and 56, respectively

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  39. Cross-sectional study: Graded and Redefined Assessment of Strength, Sensation and Prehension (GRASSP)

    GRASSP measures sensorimotor and prehension function through three domains (strength, sensation and prehension) which are important in describing arm and hand function. The total GRASSP score ranges from 0 to 116 points, where a higher score indicates a better outcome

    Time frame: Baseline only

  40. Longitudinal study: Graded and Redefined Assessment of Strength, Sensation and Prehension (GRASSP)

    GRASSP measures sensorimotor and prehension function through three domains (strength, sensation and prehension) which are important in describing arm and hand function. The total GRASSP score ranges from 0 to 116 points, where a higher score indicates a better outcome

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  41. Cross-sectional study: European Multicenter Study about SCI (EMSCI) pain questionnaire

    The EMSCI pain questionnaire rates various aspects of pain (e.g., current pain intensity, mean and maximal pain intensity during the last week before the assessment, location and quality of pain, intensity of allodynia and paresthesia). Pain intensity is quantified on an 11-point numeric scale (0=no pain; 10=worst imaginable pain)

    Time frame: Baseline only

  42. Longitudinal study: European Multicenter Study about SCI (EMSCI) pain questionnaire

    The EMSCI pain questionnaire rates various aspects of pain (e.g., current pain intensity, mean and maximal pain intensity during the last week before the assessment, location and quality of pain, intensity of allodynia and paresthesia). Pain intensity is quantified on an 11-point numeric scale (0=no pain; 10=worst imaginable pain)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  43. Cross-sectional study: sympathetic skin response including hand, sole and perineum recordings

    Latencies (units of ms)

    Time frame: Baseline only

  44. Cross-sectional study: sympathetic skin response including hand, sole and perineum recordings

    Amplitudes (units of microV)

    Time frame: Baseline only

  45. Longitudinal study: sympathetic skin response including hand, sole and perineum recordings

    Latencies (units of ms)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  46. Longitudinal study: sympathetic skin response including hand, sole and perineum recordings

    Amplitudes (units of microV)

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  47. Cross-sectional study: Spinal Cord Independence Measure (SCIM III)

    The SCIM-III ("Spinal Cord Independence Measure III") score is based on questions concerning independence of persons with a spinal cord injured. It consists of 19 items covering 3 domains, self-care, respiration and sphincter management, and mobility. The self-care subscale ranges from 0 to 20. The respiration and sphincter management subscale ranges from 0 to 40. The mobility subscale ranges from 0 to 40. Total score ranges from 0 (symptomatic) to 100 (asymptomatic). Higher scores reflect higher levels of independence.

    Time frame: Baseline only

  48. Longitudinal study: Spinal Cord Independence Measure (SCIM III)

    The SCIM-III ("Spinal Cord Independence Measure III") score is based on questions concerning independence of persons with a spinal cord injured. It consists of 19 items covering 3 domains, self-care, respiration and sphincter management, and mobility. The self-care subscale ranges from 0 to 20. The respiration and sphincter management subscale ranges from 0 to 40. The mobility subscale ranges from 0 to 40. Total score ranges from 0 (symptomatic) to 100 (asymptomatic). Higher scores reflect higher levels of independence

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  49. Cross-sectional study: Walking index for Spinal Cord Injury (WISCI)

    WISCI is an ordinal 20-point scale (0=unable to stand and/or participate in walking; 20=ambulates with no devices, with brace and no assistance) to assess walking function

    Time frame: Baseline only

  50. Longitudinal study: Walking index for Spinal Cord Injury (WISCI)

    WISCI is an ordinal 20-point scale (0=unable to stand and/or participate in walking; 20=ambulates with no devices, with brace and no assistance) to assess walking function

    Time frame: Change from baseline at 2-month, 6-month, and 12-month

  51. Longitudinal study: International Prostate Symptom Score (IPSS) (only in patients with neurogenic lower urinary tract dysfunction)

    The IPSS score is based on questions concerning urinary symptoms and quality of life (QoL). It consists of 8 items covering 7 urinary symptoms related dimensions (subscales) and 1 additional item assessing quality of life. Each item is rated on a 6-point scale (0=not at all; 5=almost always). The lowest possible score in the total IPSS score is 0 (asymptomatic); the highest possible score is 35 (symptomatic). The QoL index is rated on a 7-point scale, with 0 indicating "delighted" and 6 "terrible"

    Time frame: Change between baseline and follow-up (6-12 weeks of tibial nerve stimulation)

  52. Longitudinal study: Qualiveen questionnaire (only in patients with neurogenic lower urinary tract dysfunction)

    Qualiveen-30 assesses the Specific Impact of Urinary Problems (SIUP) on Quality of Life. It consists of 30 items covering 4 domains, namely inconvenience (9 questions), restrictions (8 questions), fears (8 questions), and impact on daily life (5 questions). Each item is rated on a 5-point ordinal scale (0=asymptomatic; 4=symptomatic). The index of the SIUP on Quality of Life is the mean of the four individual scores. The lowest possible overall score in the Qualiveen-30 is 0 (Urinary problems have no specific impact on QoL); the highest possible score is 30 (Urinary problems have a huge specific impact on QoL)

    Time frame: Change between baseline and follow-up (6-12 weeks of tibial nerve stimulation)

  53. Longitudinal study: Urinary Symptom Profile (USP) (only in patients with neurogenic lower urinary tract dysfunction)

    The USP score is based on questions concerning urinary symptoms and their severity in males and females. It consists of 13 items covering 3 dimensions (subscales) with 7 overactive bladder (OAB), 3 stress urinary incontinence (SUI), and 3 low stream (LS) related items. Each item is rated on a 4-point scale. The lowest score is 0 (asymptomatic); the highest score is 3 (symptomatic)

    Time frame: Change between baseline and follow-up (6-12 weeks of tibial nerve stimulation)

  54. Longitudinal study: Overactive Bladder (ICIQ-OAB) questionnaire (only in patients with neurogenic lower urinary tract dysfunction)

    International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life ICIQ-OAB-QoL is a 26-item questionnaire evaluating quality of life (QoL) in patients with overactive bladder. Scores range from 25-160, with greater values indicating increased impact on quality of life

    Time frame: Change between baseline and follow-up (6-12 weeks of tibial nerve stimulation)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Aug 2028, 67 months after the start.

Of 124 non-industry observational studies under Spinal Cord Injuries, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 74. This study's planned 67 months is above that.

Counting every sponsor, half of 135 studies reached it within 39 months; a quarter within 16 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2027 → Aug 2028 and completion Aug 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2022
First posted
Jan 12, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Aug 31, 2028was Aug 2027
CompletionEst.
Aug 31, 2028was Aug 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2027→Aug 31, 2028
Nov 16, 2026
Study completion
Aug 31, 2027→Aug 31, 2028
Nov 16, 2026
Contact
Study contact changed: c•••@balgrist.ch · •••7208→l•••@balgrist.ch · •••7208. See the current contact
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Aug 31, 2027→Aug 31, 2028
    Study completion Aug 31, 2027→Aug 31, 2028
    Contact Study contact changed: c•••@balgrist.ch · •••7208→l•••@balgrist.ch · •••7208. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05681936
Collaborators
Swiss National Science Foundation, Swiss Paraplegic Research, Nottwil
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
Jan 1, 2023
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Gergely David, Dr.
Contact
gergely.david@balgrist.ch
+41 44 510 72 13
Lara Faber, MSc
Contact
lara.faber@balgrist.ch
+41 44 510 72 08
Patrick Freund, Prof. Dr. med. Dr. rer. nat.
principal investigator · University of Zurich

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion